Searchable abstracts of presentations at key conferences in endocrinology

ea0084op-10-47 | Oral Session 10: Young Investigators / Clinical and Translational | ETA2022

Putative protective role of anti-nuclear antibodies in graves’ orbitopathy

Lanzolla Giulia , Comi Simone , Puccinelli Lisa , Menconi Francesca , Marcocci Claudio , Marino' Michele

Objectives: A sporadic association between thyroid and non-organ-specific autoimmunity has been reported, which could be relevant for Graves’ orbitopathy (GO), an autoimmune disease affecting orbital connective tissue. We investigated whether there is an association between GO and anti-nuclear antibodies (ANAs).Methods: We performed a cross-sectional investigation in 265 consecutive patients with Graves’ disease (GD) who came to our observation...

ea0084ps2-07-58 | Graves’ Disease 1 | ETA2022

High IGG4 serum levels in graves’ disease compared with nonautoimmune hyperthyroidism

Comi Simone , Lanzolla Giulia , Giudetti Matilde , Menconi Francesca , Marcocci Claudio , Marino Michele

Objectives: A role of IgG4 in Graves’ disease (GD) has been proposed, although the available data are conflicting. In addition, an association between Graves’ orbitopathy (GO) and IgG4-related disease has been postulated, but no firm demonstration has been obtained. Thus, the aim of the present study was to investigate the role of IgG4 in GD.Methods: We performed a cross-sectional investigation in 351 consecutive patients (F=284, M=67; age 48.2...

ea0063p708 | Pituitary and Neuroendocrinology 2 | ECE2019

Hypophysitis secondary to anti-pd1/pd-l1 blockade: variations in presentation, four distinct cases

Lanzolla Giulia , Viola Nicola , Brancatella Alessandro , Latrofa Francesco , Marcocci Claudio , Vitti Paolo , Lupi Isabella

PD-1/PD-L1 pathway is a key regulator in T-cell activation and tolerance. Nivolumab, pembrolizumab (a PD-1 inhibitors) and atezolizumab (a PD-L1 inhibitor) are monoclonal antibodies approved for treatment of advanced cancers. Autoimmune thyroid diseases are the most common immune-related adverse effects (IrAEs) occurring after anti-PD-1 or anti-PD-L1 therapy, whereas autoimmune hypophysitis is described more frequently in patients treated with anti-CTLA-4. IrAEs can be isolate...

ea0063p765 | Thyroid 2 | ECE2019

Thyroid disfunction during treatment with Nivolumab: nuances in clinical presentation

Brancatella Alessandro , Viola Nicola , Lanzolla Giulia , Vitti Paolo , Marcocci Claudio , Latrofa Francesco , Lupi Isabella

Context: Monoclonal antibodies to Immune Check Point inhibitors (ICPis) are powerful anti-cancer drugs. They trigger the immune system against cancer cells, blocking inhibitory signals of T-Cells. However, ICPi therapy can also stimulate autoimmune reactions, inducing the so-called immune-related adverse events (irAEs). Endocrinopathies are common iRAEs and thyroid disfunction is the most common endocrinopathy during ICP therapy. We report three cases of thyroid disfunction du...

ea0084op-05-24 | Oral Session 5: Autoimmunity | ETA2022

Sirolimus for graves’ orbitopathy: A novel drug for the management of patients with moderate-to-severe graves’ orbitopathy?

Lanzolla Giulia , Novella Maglionico Maria , Comi Simone , Menconi Francesca , Posarelli Chiara , Figus Michele , Marcocci Claudio , Marino' Michele

Background: Sirolimus is an immunosuppressive drug with anti-fibrotic and anti-proliferative activities. In vitro, sirolimus inhibits differentiation of orbital fibroblasts from patients with Graves’ orbitopathy (GO), suggesting a possible use in clinical practice.Methods: We performed a retrospective investigation aimed at evaluating the effects of sirolimus as a second-line treatment for moderate-to-severe, active GO, compared with methyl...

ea0092ps2-15-01 | Hyperthyroidism | ETA2023

A prospective, observational study on the effect of an ablative vs a conservative approach for the treatment of graves’ hyperthyroidism in patients with moderate-to-severe, active graves’ orbitopathy

Cosentino Giada , Lanzolla Giulia , Comi Simone , Menconi Francesca , Rotondo Dottore Giovanna , Novella Maglionico Maria , Posarelli Chiara , Figus Michele , Elisei Rossella , Santini Ferruccio , Marino Michele

Objectives: Optimal treatment for Graves’ hyperthyroidism (GH) in patients with moderate-to-severe, active Graves’ orbitopathy (GO) remains to be established. There is debate on whether a conservative (antithyroid drugs, ATDs) or an ablative approach (radioactive iodine, RAI, or surgery, Tx)has to be preferred. The aim of the present study was to investigate whether these different approachesresult in a different outcome of GOfollowing intravenous glucocorticoids (iv...

ea0092ps3-24-02 | Thyroid Eye Disease | ETA2023

Long-Term outcome of moderate-to-severe, active graves’ orbitopathy following treatment with sirolimus (Ramamycin): results in a case series

Comi Simone , Lanzolla Giulia , Cosentino Giada , Menconi Francesca , Novella Maglionico Maria , Posarelli Chiara , Leni Lorenzo , Figus Michele , Elisei Rossella , Santini Ferruccio , Marino Michele

Objectives: Sirolimus is an immunosuppressive drug with anti-fibrotic and anti-proliferative activities. In a recent study, sirolimus (given off-label as a second-line treatment) was found to be associated with a better outcome of Graves’ orbitopathy (GO) at 6 months compared to the standard treatment (intravenous glucocorticoids). Here we investigated the effects of sirolimus over a longer period of time.Methods: The study design entailed data anal...